Calgary, AB – TheNewswire - December 19, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announced (November 25, 2025) brokered private placement (the “Offering”) on a best-efforts basis led by Centurion One Capital Corp. (the “Lead Agent”), the Corporation has amended the
Calgary, Alberta – TheNewswire - December 9, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to
https://youtu.be/bcardmns2c0
Dear Investors,I have received several inquiries about our October 8th press release. It marks an exciting and historic milestone for Ocumetics. The patients selected for our first clinical group entered the study with very poor functional vision due to cataracts and were struggling to see clearly at distance.One month following cataract surgery and implantation of
Ocumetics Director and CEO, Dean Burns covers important updates on our first-in-human (FIH) study and what lies ahead. Topics include: Encouraging outcomes from initial surgeries Next steps to complete the FIH study Live Q&A session with Dean Burnshttps://youtu.be/rWQnOaq6sVE
This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed.I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief into
Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens.What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of years
Ocumetics Director and CEO, Dean Burns, covers key details of our upcoming first-in-human study and recently opened private placement financing. Topics will include:Final steps leading up to the first-in-human studyDetails on the now-open private placement investment opportunityLive Q&A session with Dean BurnsThanks to everyone who joined us for the Webinar. It was an amazing turnout,
Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including:First-in-human study timingRemaining steps to first-in-human studyQ&A sessionThanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!https://youtu.be/NmBiGLHMhFo
Today marks a defining moment in the history of Ocumetics—and in the future of vision restoration worldwide.It is with great pride and anticipation that I share we are now entering the final stages before our First-In-Human (FIH) clinical study for the Ocumetics Lens. This is more than a corporate milestone; it is the beginning of
TSX-V:OTC | OCTQB: OTCFF | FSE: 2QB0
#1250 – 639 5th Ave SW
Calgary AB T2P 0M9
Canada
